Multimodal activity contributes to efficacy while local targeting diminishes risk of off-target effects including immunosuppression
ADISO DEVELOPMENT PORTFOLIO


First-In-Class Small Molecule Modulator of Neutrophil Trafficking and Activation
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS051
Portfolio of First-In-Class Small Molecule Inhibitors of the NLRP3 and 1 Inflammasomes
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS032
ADISO PARTNERING PORTFOLIO

Portfolio of Single Strain Live Biotherapeutic Products (SS-LBP)
Discovery
IND Enabling
Phase 1
Phase 2
Phase 3
ADS024 CDI
ADS024 UC
ADS012